Initiation of subcutaneous infliximab (Remsima) therapy for the treatment of inflammatory bowel disease during the COVID-19 pandemic

Promising evidence in the subcutaneous (SC) administration of the infliximab (IFX) biosimilar CT-P13 (Remsima) has emerged in recent years. Furthermore, immunogenicity data have suggested superior steady-state therapeutic blood levels of IFX and lower rate of anti-IFX antibodies in a cohort of patients receiving SC Remsima following two intravenous induction doses in contrast to their counterparts who continued to receive intravenous therapy.\(^1\)\(^2\) In response to the challenges posed by the COVID-19 pandemic to patients with inflammatory bowel disease (IBD) receiving IFX, we embarked on a patient-partnered programme in switching to SC Remsima. Seventy-five individuals were included in the preliminary service development and some demographics are outlined in Table 1. An assessment of patients’ attitudes was conducted using a survey.

Once patients agreed to change to SC Remsima, they were sent information via email, with contact information and a link to an instructional video which can be found here https://www.youtube.com/watch?v=KUaxysZxbU0. From 30 March 2020 to 15 May 2020, 75 patients had received SC Remsima.

Forty-one patients returned surveys before the end of July 2020, representing a 54.7% return. Twenty-five (61.0%) participants clearly indicated feelings of apprehension and anxiety prior to starting SC Remsima, with a majority of respondents counter this by expressing positive outlooks on changing therapy to a SC form. The emergence of the COVID-19 pandemic and measures taken to alter healthcare provision had a major impact on patients’ impressions of their treatment. The convenience of avoiding hospital appointments for intravenous infusion therapy and the enhanced control afforded by this therapy were commonly perceived benefits.

The majority of adverse events related to injection site problems like pain and swelling, with at least 12 (29.3%) experiencing such issues. This was the most commonly cited reason for opting to return to intravenous IFX. Besides concerns about injection site issues, suggestions for improvement focused on better interaction between healthcare provider and patient. Clear benefits of attending hospital were espoused by some respondents, from potentially obvious to the team: ‘I found the observations done before the IV very useful’; to more unique insights: ‘As someone who lives alone there was a ‘social’ element of hospital attendance’.

Healthcare provider experiences and patient feedback have demonstrated a successful transition from intravenous to SC IFX for the majority. The early identification of pitfalls is essential in achieving a sustainable service of good quality. A patient-centred approach will mean catering also to those who may find it difficult to adapt. As one of the first centres to establish SC Remsima for our IBD patient group, this has been an insightful experience that will

Table 1: Demographic details of patients undergoing intravenous to subcutaneous infliximab switch

| Number (%) |
|------------|
| Total patients | 75 (100) |
| Male         | 44 (58.7) |
| Female       | 31 (41.3) |
| Crohn’s disease | 61 (81.3) |
| Ulcerative colitis | 14 (18.7) |
| Median age   | 37       |
Letters

guide better approaches to holistic care in the future.

John McGoran,1 Alan Wilson,2 Shannan McErlain,3 Noreen Kennedy,1 Caroline Masterson,1 Caroline Collins,1 Graham Morrison1

1Gastroenterology, Belfast Health and Social Care Trust, Belfast, UK
2Pharmacy, Belfast Health and Social Care Trust, Belfast, UK

Correspondence to Dr Graham Morrison, Gastroenterology, Belfast Health and Social Care Trust, Belfast BT13 1FD, UK; graham.morrison@belfasttrust.hscni.net

Contributors JMG is lead author and designed the patient survey. AW led the initial service improvement and contributed to the article. SME supported the service development and contributed to the article. NK supported the service development and contributed to the article. CM supported the service development and contributed to the article. GM was clinical lead for service development and is senior author.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

To cite McGoran J, Wilson A, McErlain S, et al. Frontline Gastroenterology 2022;13:89–90.

Received 20 December 2020
Revised 8 April 2021
Accepted 18 April 2021
Published Online First 27 May 2021

Frontline Gastroenterology 2022;13:89–90. doi:10.1136/flgastro-2020-101760

ORCID iD
John McGoran http://orcid.org/0000-0002-9514-5290

REFERENCES

1 Yoo D-H, Westhovens R, Ben-Horin S. Development of a subcutaneous formulation of CT-P13 (infliximab): maintenance subcutaneous administration may elicit lower immunogenicity compared to intravenous treatment. Arthritis Rheumatol 2018;70:

2 Albshesh A, Ben-Horin S. CT-P13: a review on a biosimilar to infliximab in the treatment of inflammatory bowel disease. Expert Opin Biol Ther 2019;19:971–8.